# A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

> **NCT06257758** · PHASE1,PHASE2 · TERMINATED · sponsor: **Valerio Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumors
- Breast Cancer
- Recurrent Ovarian Cancer
- Prostate Cancer

## Interventions

- **DRUG:** VIO-01

## Key facts

- **NCT ID:** NCT06257758
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-10
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06257758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06257758, "A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06257758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*